Skip to main content
OpenTrials
Completed

NCT Number: NCT06887504

The Evaluation of White Matter Intensities in Patients with Pediatric Epilepsy

Aim: Neuroimaging is an important tool, in combination with a detailed medical history, physical examination, and electroencephalography, in the diagnosis and classification of epilepsy. White matter hyperintensities (WMHs) are bright areas of high signal intensity seen in white matter at T2-weighted MRI. Researchers aimed to evaluate whether white matter hyperintensities are more common in children with epilepsy.

Material-method: Patients who underwent cranial MRI with diagnoses of epilepsy based on International League Against Epilepsy (ILAE) criteria at the Balıkesir University Medical Faculty Pediatric neurology clinic, Türkiye, between 01.08.2019 and 01.03.2024 and patients who underwent cranial MRI during the same period due to indications other than epilepsy, such as headache, syncope, and vertigo, were included in the study. Written informed consent was received from all patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–16 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mersin University

Mersin, Turkey, 33343, Turkey (Türkiye)

About this study

Aim: Neuroimaging is an important tool, in combination with a detailed medical history, physical examination, and electroencephalography, in the diagnosis and classification of epilepsy. White matter hyperintensities (WMHs) are bright areas of high signal intensity seen in white matter at T2-weighted MRI. Researchers aimed to evaluate whether white matter hyperintensities are more common in children with epilepsy.

Material-method: Patients who underwent cranial MRI with diagnoses of epilepsy based on International League Against Epilepsy (ILAE) criteria at the Balıkesir University Medical Faculty Pediatric neurology clinic, Türkiye, between 01.08.2019 and 01.03.2024 and patients who underwent cranial MRI during the same period due to indications other than epilepsy, such as headache, syncope, and vertigo, were included in the study. Written informed consent was received from all patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cranial MRI during the same period due to indications other than epilepsy;

  • headache
  • syncope and
  • vertigo

Exclusion criteria

Patients with neuropsychiatric disorders;

  • depression,
  • psychotic disorders,
  • autism spectrum disorder History of medication use for any chronic disease other than seizure medication, History of vascular disease ;
  • Collagen tissue diseases;
  • lupus,
  • juvenile rheumatoid arthritis,
  • polyarteritis nodosa,
  • Kawasaki disease Demyelinating disease
  • acute demyelinating disease (ADEM),
  • Multiple sclerosis Acute symptomatic seizure or a single unprovoked seizure, İncomplete file data, or MRI performed at a location other than our hospital

Treatment and study plan

Primary outcomes

  1. The Evaluation of White Matter Intensities in Patients with Pediatric Epilepsy

    Time frame: 01.08.2019 and 01.03.2024

    To determine whether white matter hyperintensities are more frequent in children with epilepsy by comparing epilepsy and control groups.

  2. The Evaluation of White Matter Intensities in Patients with Pediatric Epilepsy

    Time frame: 01.08.2019 and 01.03.2024

    Better understanding the association between pediatric epilepsy patients and white matter changes.

Sponsors and collaborators

Lead sponsor

Aysen Orman

Other

Registry information

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Mar 20, 2025
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.